Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879975 | 0.90 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL1532519 | 0.90 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8941498 | 0.90 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28250490 | 0.89 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29508997 | 0.88 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18954926 | 0.88 | P2RY14 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL9644061 | 0.88 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4849439 | 0.88 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6389231 | 0.88 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2546576 | 0.87 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4244356-A1 | CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2 | Dicerna Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022104366-A1 | CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2 | DICERNA PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220088097-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2022-03-24 | — | — | US | claimed |
| EP-3528821-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | ModernaTX, Inc. (US) | 2019-08-28 | — | — | EP | claimed |
| WO-2018170270-A1 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | claimed |
| WO-2018075980-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2018-04-26 | — | — | WO | claimed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026104670-A1 | VARIANTS OF EPSTEIN-BARR VIRUS GLYCOPROTEIN B, NUCLEIC ACIDS ENCODING THE SAME, AND USES THEREOF | SANOFI PASTEUR (FR) | 2026-05-21 | — | — | WO | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2002042423-A2 | ANTISENSE MODULATION OF SRC-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| CN-1347418-A | Novel nucleosides and oligonucleotide analogues | SANKYO CO (JP) | 2002-05-01 | — | — | CN | disclosed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | disclosed |
| US-4866035-A | Dipeptidyl saccharides as host resistance enhancers in AIDS-immuno-compromised hosts and methods of use | MERCK & CO., INC. (US) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | SLC28A1 891/4885SLC28A2 952/4885SLC29A1 304/4885 |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PSEN1, CD44, CD47 | SLC28A1 2596/4885SLC28A2 2626/4885SLC29A1 1796/4885 |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | CSGALNACT1, LY96, C5AR2 | SLC28A1 2949/4885SLC28A2 1392/4885SLC29A1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.